Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1561-1570 of 1,873) with videos related to

Pageof 188
Sort By:
JACC. Heart Failure|April 4, 2024
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVERJawad H Butt, Pardeep S Jhund, Kieran F Docherty, et al.
JAMA Cardiology|January 24, 2024
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER TrialOrly Vardeny, Akshay S Desai, Pardeep S Jhund, et al.
Circulation. Heart Failure|August 30, 2024
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF TrialHenri Lu, Safia Chatur, Sahmin Lee, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.
Circulation|November 19, 2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HFFelipe A Martinez, Matteo Serenelli, Jose C Nicolau, et al.
European Journal of Heart Failure|January 22, 2022
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HFKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
JAMA Network Open|December 20, 2023
Electronically Delivered Nudges to Increase Influenza Vaccination Uptake in Older Adults With Diabetes: A Secondary Analysis of the NUDGE-FLU TrialMats C Højbjerg Lassen, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
Journal of Cardiac Failure|September 27, 2023
Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure RegistryAnkeet S Bhatt, Gregg C Fonarow, Stephen J Greene, et al.
Pageof 188

Showing results (1561-1570 of 1,873) with videos related to

Sort By:
Pageof 188
JACC. Heart Failure|April 4, 2024
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVERJawad H Butt, Pardeep S Jhund, Kieran F Docherty, et al.
JAMA Cardiology|January 24, 2024
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER TrialOrly Vardeny, Akshay S Desai, Pardeep S Jhund, et al.
Circulation. Heart Failure|August 30, 2024
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF TrialHenri Lu, Safia Chatur, Sahmin Lee, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.
Circulation|November 19, 2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HFFelipe A Martinez, Matteo Serenelli, Jose C Nicolau, et al.
European Journal of Heart Failure|January 22, 2022
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HFKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
JAMA Network Open|December 20, 2023
Electronically Delivered Nudges to Increase Influenza Vaccination Uptake in Older Adults With Diabetes: A Secondary Analysis of the NUDGE-FLU TrialMats C Højbjerg Lassen, Niklas Dyrby Johansen, Muthiah Vaduganathan, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
Journal of Cardiac Failure|September 27, 2023
Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure RegistryAnkeet S Bhatt, Gregg C Fonarow, Stephen J Greene, et al.
Pageof 188